← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Aldatu Biosciences, Inc.
Watertown, MA
$17,409,633
Total funding
8
Grants
Funding over time
peak $4M · FY2015–25$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$17,409,633 · 8
By mechanism
R44$10,898,319 · 4
N01$2,980,467 · 1
SB1$2,932,453 · 1
R43$299,704 · 1
N43$298,690 · 1
Investigators at Aldatu Biosciences, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
ExPAND for Rapid, Sensitive, Cost-effective Detection of Drug-resistant HIV Minority Variants$2,980,467
N01 · FY2018 · AI
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$998,024
R44 · FY2017 · AI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$992,797
SB1 · FY2022 · AI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.$986,903
R44 · FY2024 · AI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$981,812
SB1 · FY2023 · AI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus.$975,023
R44 · FY2025 · AI
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$973,600
R44 · FY2018 · AI
PANDAA for rapid genotyping of HIV-1 infected patients failing protease inhibitor ART in resource-limited settings$966,696
R44 · FY2019 · AI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$964,499
R44 · FY2022 · AI
Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings.$957,844
SB1 · FY2024 · AI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$943,229
R44 · FY2024 · AI
PANDAA for universal, pan-lineage molecular detection of filoviruses to enable rapid epidemic response.$931,246
R44 · FY2023 · AI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$865,501
R44 · FY2021 · AI
PANDAA for universal, pan-lineage molecular detection of Crimean-Congo Hemorrhagic Fever virus$829,151
R44 · FY2022 · AI
A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings$773,398
R44 · FY2015 · AI
A Rapid, Cost-Effective HIV Drug Resistance Diagnostic for Resource-Limited Settings$691,049
R44 · FY2016 · AI
PANDAA for universal, pan-lineage molecular detection of Lassa fever infection$299,704
R43 · FY2019 · AI
IGF::OT::IGF PANDAA FOR RAPID, SENSITIVE, COST-EFFECTIVE DETECTION OF DRUG-RESISTANT HIV MINORITY VARIANTS$298,690
N43 · FY2016 · AI